Advaxis (ADXS) Posts Earnings Results

Advaxis (NASDAQ:ADXS) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.06, Yahoo Finance reports. Advaxis had a negative net margin of 776.63% and a negative return on equity of 114.00%. The business had revenue of $2.06 million during the quarter, compared to analysts’ expectations of $3.03 million.

Shares of Advaxis (ADXS) traded down $0.34 during trading hours on Tuesday, hitting $1.87. 1,561,027 shares of the company’s stock were exchanged, compared to its average volume of 1,159,203. Advaxis has a 1-year low of $1.75 and a 1-year high of $9.55. The stock has a market cap of $112.65, a PE ratio of -0.96 and a beta of 1.06.

A number of equities analysts have commented on the stock. Cantor Fitzgerald set a $5.00 price objective on shares of Advaxis and gave the stock a “buy” rating in a research note on Tuesday. ValuEngine raised shares of Advaxis from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, HC Wainwright set a $23.00 price objective on shares of Advaxis and gave the stock a “buy” rating in a research note on Wednesday, December 27th.

COPYRIGHT VIOLATION WARNING: This piece was reported by Markets Daily and is owned by of Markets Daily. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Earnings History for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with's FREE daily email newsletter.

Leave a Reply